Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/IIa, First-in-Human, Open-Label Study to Evaluate the Safety, Tolerability, and Exploratory Activity of BETA-TT8 Ophthalmic Gel 3.8% in Patients With Neovascular (Wet) Age-related Macular Degeneration (wetAMD)

NCT07766473 is registered in ClinicalTrials.gov with Filamon LTD as lead sponsor.

NCT NCT07766473
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07766473 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/IIa, First-in-Human, Open-Label Study to Evaluate the Safety, Tolerability, and Exploratory Activity of BETA-TT8 Ophthalmic Gel 3.8% in Patients With Neovascular (Wet) Age-related Macular Degeneration (wetAMD)
Lead sponsor
Filamon LTD
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
September 30, 2027
Enrollment
24 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

neovascular (wet) age-related macular degeneration